Canada · Delayed Price · Currency is CAD Hydreight Technologies Statistics
Total Valuation
TSXV:NURS has a market cap or net worth of CAD 212.52 million. The enterprise value is 197.26 million.
| Market Cap | 212.52M |
| Enterprise Value | 197.26M |
Important Dates
The last earnings date was Monday, June 1, 2026.
| Earnings Date | Jun 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:NURS has 53.67 million shares outstanding. The number of shares has increased by 24.44% in one year.
| Current Share Class | 53.67M |
| Shares Outstanding | 53.67M |
| Shares Change (YoY) | +24.44% |
| Shares Change (QoQ) | +1.99% |
| Owned by Insiders (%) | 1.88% |
| Owned by Institutions (%) | 1.06% |
| Float | 27.06M |
Valuation Ratios
The trailing PE ratio is 44.58 and the forward PE ratio is 10.42.
| PE Ratio | 44.58 |
| Forward PE | 10.42 |
| PS Ratio | 3.81 |
| PB Ratio | 5.84 |
| P/TBV Ratio | 6.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 46.30 |
| EV / Sales | 3.54 |
| EV / EBITDA | 39.99 |
| EV / EBIT | 44.76 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.63, with a Debt / Equity ratio of 0.25.
| Current Ratio | 5.63 |
| Quick Ratio | 5.04 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 1.83 |
| Debt / FCF | -1.26 |
| Interest Coverage | 4.15 |
Financial Efficiency
Return on equity (ROE) is 21.54% and return on invested capital (ROIC) is 11.09%.
| Return on Equity (ROE) | 21.54% |
| Return on Assets (ROA) | 9.03% |
| Return on Invested Capital (ROIC) | 11.09% |
| Return on Capital Employed (ROCE) | 9.65% |
| Weighted Average Cost of Capital (WACC) | 8.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 1.84 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -580,337 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +107.33% in the last 52 weeks. The beta is 0.73, so TSXV:NURS's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | +107.33% |
| 50-Day Moving Average | 3.92 |
| 200-Day Moving Average | 3.99 |
| Relative Strength Index (RSI) | 44.56 |
| Average Volume (20 Days) | 140,383 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TSXV:NURS had revenue of CAD 55.78 million and earned 4.26 million in profits. Earnings per share was 0.09.
| Revenue | 55.78M |
| Gross Profit | 12.58M |
| Operating Income | 4.38M |
| Pretax Income | 3.68M |
| Net Income | 4.26M |
| EBITDA | 4.90M |
| EBIT | 4.38M |
| Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 24.21 million in cash and 8.96 million in debt, with a net cash position of 15.25 million or 0.28 per share.
| Cash & Cash Equivalents | 24.21M |
| Total Debt | 8.96M |
| Net Cash | 15.25M |
| Net Cash Per Share | 0.28 |
| Equity (Book Value) | 36.41M |
| Book Value Per Share | 0.68 |
| Working Capital | 32.02M |
Cash Flow
In the last 12 months, operating cash flow was -7.09 million and capital expenditures -5,428, giving a free cash flow of -7.09 million.
| Operating Cash Flow | -7.09M |
| Capital Expenditures | -5,428 |
| Depreciation & Amortization | 525,985 |
| Net Borrowing | 10.12M |
| Free Cash Flow | -7.09M |
| FCF Per Share | -0.13 |
Margins
Gross margin is 22.56%, with operating and profit margins of 7.85% and 7.64%.
| Gross Margin | 22.56% |
| Operating Margin | 7.85% |
| Pretax Margin | 6.60% |
| Profit Margin | 7.64% |
| EBITDA Margin | 8.79% |
| EBIT Margin | 7.85% |
| FCF Margin | n/a |
Dividends & Yields
TSXV:NURS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.44% |
| Shareholder Yield | -24.44% |
| Earnings Yield | 2.00% |
| FCF Yield | -3.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for TSXV:NURS is 9.25, which is 133.59% higher than the current price. The consensus rating is "Buy".
| Price Target | 9.25 |
| Price Target Difference | 133.59% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on November 25, 2022. It was a reverse split with a ratio of 0.1546061.
| Last Split Date | Nov 25, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.1546061 |
Scores
TSXV:NURS has an Altman Z-Score of 7.76 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.76 |
| Piotroski F-Score | 3 |